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n a new research article published 
in PLoS Medicine, Francoise Dromer 
and colleagues [1] report on a 
French national prospective study (the 
“CryptoA/D” study) of the factors 
inﬂ  uencing clinical presentation and 
outcome of patients with cryptococcosis 
(an infection caused by the pathogenic 
fungus Cryptococcus neoformans). This is 
just the type of prospective study that 
is needed to help us understand how 
we are doing in the management of a 
life-threatening infection. Often our 
randomized, blinded, and controlled 
studies do not reﬂ  ect actual outcomes 
in the general medical community, 
because study participants are biased 
by a series of entry criteria and other 
issues. Thus, prospective studies to 
collect real-time data during clinical 
management become important gauges 
in how successful we are and may help 
us deﬁ  ne what we need to improve. 
The New Study
Dromer and colleagues present a 
multicenter surveillance of an entire 
country’s experience of cryptococcosis 
management over a four-year period. 
Their study of 230 patients came to 
three major conclusions. 
First, from the initial assessment, 
higher severity of illness and poorer 
outcome occurred in: (1) men; (2) 
HIV-positive patients; and (3) patients 
infected with serotype A strains. These 
three factors capture three potential 
issues of: genetic susceptibility and/or 
hormonal inﬂ  uences, host immunity, 
and strain virulence or microbial ﬁ  tness 
in cryptococcosis. Many years ago, the 
importance of male sex and outcome 
of cryptococcosis was observed in 
controlled animal experiments [2]. 
In cryptococcosis, host immunity 
inﬂ  uences the production of disease 
and disease outcome, and cell-
mediated immunity is always the 
focal point in this infection. The 
host immune system, which can be 
altered by HIV infection or high-
dose corticosteroids, controls the 
appearance and severity of cryptococcal 
infection (Figure 1). Finally, the 
particular invading cryptococcal strain 
may have some impact on disease. 
In animals cryptococcal strains vary 
in their ability to produce disease 
with the same inoculum, and in the 
Dromer et al. human study serotype A 
strains were more likely than serotype 
D strains to produce severe disease. 
Further validation of the importance of 
speciﬁ  c strains on disease is illustrated 
by the large outbreak of Cryptococcus 
gattii on Vancouver Island, Canada, 
in immunocompetent hosts with a 
probable recombinant hypervirulent 
strain [3]. 
The second ﬁ  nding of this study 
is the direct mycological impact of 
treatment. With the use of an endpoint 
at two weeks of mycological failure 
(deﬁ  ned as at least one cultured 
sample from the patient containing 
viable C. neoformans), the researchers 
found that failure was associated with 
initial dissemination of infection, high 
serum antigen titers, and the lack 
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Figure 1. Cryptococcosis of the Lung in a Patient with AIDS
Histopathology of lung shows widened alveolar septa containing a few inﬂ  ammatory cells and 
numerous yeasts of the fungal pathogen C. neoformans. The inner layer of the yeast capsule stains 
red. Cryptococcosis is transmitted through inhalation of airborne yeast cells and/or biospores. At 
risk are the immunocompromised, especially those with HIV infection. Photo: CDC/Dr. Edwin P. 
Ewing, Jr.PLoS Medicine  |  www.plosmedicine.org 0233
of ﬂ  ucytosine use during induction 
therapy. It is clear that patients with 
a high burden of organisms are at 
risk for failure, and initial cultures of 
several body sites and antigen titers 
can help identify these high-risk 
patients. This study also continues 
to validate the strategy of using the 
combination therapy of amphotericin 
B plus ﬂ  ucytosine [4]. The beneﬁ  ts of 
adding ﬂ  ucytosine are related to its 
faster “sterilization” of tissue and ﬂ  uids 
[5], and the combination approach 
is associated with fewer relapses 
compared with monotherapy [6].
Third, this study identiﬁ  ed the three 
factors that contributed to reduced 
three-month survival: (1) abnormal 
neurology, (2) abnormal brain imaging 
at baseline, and (3) underlying 
hematological malignancy. When there 
is more disease produced by infection, 
the outcome is worse and our vigilance 
in care must be even greater. On the 
other hand, for many of these invasive 
fungal infections the ﬁ  nal arbiter of 
success will be the underlying disease 
and unfortunately, this issue may 
be difﬁ  cult to control. For example, 
several decades ago Kaplan et al. noted 
that there was a poor prognosis for 
the combination of cryptococcosis 
and malignancy [7]; this fact has not 
changed.
Implications of the Study
This study allows us to observe 
where we are in the management 
of cryptococcosis in the era of 
HAART (highly active antiretroviral 
therapy) and with access to current 
antifungal drugs and supportive care. 
Unfortunately, the failure rates remain 
substantial, with a mortality of about 
12% at three months. Furthermore, 
there are undeﬁ  ned costs of care and 
morbidity from this infection. The 
question is: How do we do better? 
Next Steps
The answer is we must perform careful 
evidence-based studies to address a 
series of important clinical questions 
on patients at high risk for failure 
(see Box 1). We can then adjust our 
treatment guidelines to better ﬁ  t the 
individual patient. This evidence-
based directed research strategy will 
be good for the future of medicine 
but does not necessarily help the 
patient today. Therefore, the basic 
message of Dromer et al. rings as true 
as the message from the prognostic 
studies of cryptococcal meningitis with 
amphotericin B treatment in 1974 
[8]. In the initial management of 
cryptococcosis, the assessment of the 
burden of yeasts in the host from its site 
of infection(s) to its quantity of yeasts 
determined through cultures, antigen 
loads, and radiographic appearances 
will give clinicians a prediction of 
the difﬁ  culties that they might face. 
Furthermore, the initial philosophy 
in the high-risk patient is to provide 
therapies that efﬁ  ciently eliminate 
yeasts from the host. The sugar-coated 
killer whose sweetness sickens must 
be stripped away leaving only the 
underlying disease to deal with [9].
In their study, Dromer and 
colleagues have provided us with a 
careful gauge of how we are doing 
with this life-threatening infection. 
In some respects, clinicians should 
be congratulated for their skills in 
caring for this deadly infection. On 
the other hand, there still remains 
a need for better strategies and 
treatments for cryptococcosis in all 
patients who suffer from the disease. 
Speciﬁ  c guidelines for management 
of cryptococcosis are helpful [10], 
and studies regarding risk factors 
provide insight, but until we have 
further evidence-based understanding, 
cryptococcosis treatment in some 
patients can have bedside nuances 
requiring judgments and adjustments 
one patient at a time.  
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Box 1. Questions Needing 
Precise Answers in the 
Management of Cryptococcosis
1. What is the optimal management of 
increased intracranial pressure during 
meningitis?
2. How to speciﬁ  cally diagnose immune 
reconstitution syndrome (IRS) in 
cryptococcal meningitis and how to 
manage it?
3. During HIV infection and cryptococcal 
meningitis, when is it best to initiate 
HAART? For instance, is it different in 
resource-poor countries where azoles 
with less fungicidal activity have to be 
the inducing regimens for treatment?
4. Which is better to use: amphotericin 
B deoxycholate or lipid product of 
amphotericin B with ﬂ  ucytosine for 
induction therapy in cryptococcal 
meningitis?
5. Should we use the induction, clearance 
and suppression treatment strategy 
for all patients with cryptococcal 
meningitis and for how long should 
each stage be used? For instance, 
should patients with higher burden 
of yeasts have a longer treatment 
regimen at the induction and/or 
clearance stages?
6. When and how to use immune 
modulation during cryptococcal 
meningitis (gamma interferon for 
enhancement versus corticosteroids 
for depression of immunity in IRS)?
7. Do we need to serotype and perform 
in vitro susceptibility testing for each 
initial isolate?
8. When do we need to sample CSF 
when cryptococcus is isolated from an 
extraneural site?
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